The COVID-19 Resource Centre, established by Elsevier in January 2020, provides free information in English and Mandarin on the novel coronavirus. The centre is hosted on Elsevier Connect and grants permission for all COVID-19-related research to be immediately available in PubMed Central and other public repositories, with unrestricted reuse and analysis rights. Fang Liu et al. conducted a retrospective cohort study to investigate the prognostic value of interleukin-6 (IL-6), C-reactive protein (CRP), and procalcitonin (PCT) in predicting mild and severe cases of COVID-19. The study included 140 patients diagnosed with COVID-19 from January 18, 2020, to March 12, 2020, divided into a mild group (n = 107) and a severe group (n = 33). The levels of IL-6, CRP, and PCT were significantly higher in the severe group compared to the mild group. Cox proportional hazard models showed that IL-6 and CRP could predict the severity of COVID-19, with optimal thresholds of 32.1 pg/mL for IL-6 and 41.8 mg/L for CRP. Patients with higher levels of these markers were more likely to develop severe complications. The study highlights the significant role of inflammatory markers in predicting the severity of COVID-19. IL-6 and CRP were found to be independent factors in predicting disease severity, while the validity of PCT as an independent predictor requires further investigation. The study also emphasizes the importance of inflammatory responses in the progression of COVID-19 and the potential of these markers in guiding treatment decisions.The COVID-19 Resource Centre, established by Elsevier in January 2020, provides free information in English and Mandarin on the novel coronavirus. The centre is hosted on Elsevier Connect and grants permission for all COVID-19-related research to be immediately available in PubMed Central and other public repositories, with unrestricted reuse and analysis rights. Fang Liu et al. conducted a retrospective cohort study to investigate the prognostic value of interleukin-6 (IL-6), C-reactive protein (CRP), and procalcitonin (PCT) in predicting mild and severe cases of COVID-19. The study included 140 patients diagnosed with COVID-19 from January 18, 2020, to March 12, 2020, divided into a mild group (n = 107) and a severe group (n = 33). The levels of IL-6, CRP, and PCT were significantly higher in the severe group compared to the mild group. Cox proportional hazard models showed that IL-6 and CRP could predict the severity of COVID-19, with optimal thresholds of 32.1 pg/mL for IL-6 and 41.8 mg/L for CRP. Patients with higher levels of these markers were more likely to develop severe complications. The study highlights the significant role of inflammatory markers in predicting the severity of COVID-19. IL-6 and CRP were found to be independent factors in predicting disease severity, while the validity of PCT as an independent predictor requires further investigation. The study also emphasizes the importance of inflammatory responses in the progression of COVID-19 and the potential of these markers in guiding treatment decisions.